Add BrightSurf on Google Email

Advanced imaging uncovers genomic Achilles’ heel that makes cancer cells vulnerable

A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors. Researchers used ultrasensitive molecular imaging to pinpoint replication problems at critical chromosome regions, revealing a genomic Achilles' heel that drives drug sensitivity.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Cell Biology·TypeExperimental study·DateNov 5, 2026

Study reveals distinct cellular and genetic differences in colorectal cancer in younger patients

Researchers identified age-associated differences in tumor composition and gene activity in younger patients with colorectal cancer, including a higher proportion of connective cells and long non-coding RNAs. These differences may contribute to chemotherapy resistance and increased cancer aggression in younger adults.

SourceMass General Brigham·JournalNature Medicine·TypeExperimental study·DateOct 29, 2026

Cancer cells killed with their own carbon monoxide

Researchers at RIKEN have developed a synthetic compound that uses excess carbon monoxide produced by cancer cells to trigger the production of anti-cancer drugs within the cells themselves. The compound selectively targets tumors and avoids harming healthy cells, offering a promising new approach to cancer treatment.

SourceRIKEN·JournalNature Communications·DateOct 22, 2026

Mount Sinai study uncovers how loss of the critical tumor suppressor p53 enables mutant cells to expand through normal tissue

A Mount Sinai study reveals that loss of p53 can reorganize Wnt signaling into a radial gradient, allowing mutant cells to expand through normal tissue. The researchers found that the spatial organization of Wnt signaling, rather than its overall activity, plays a critical role in this process.

Mass spectrometry offers faster look at the edges of brain tumors

Researchers developed a mass spectrometry method to analyze tissue during brain tumor surgery, distinguishing glioma from non-tumor tissue with high confidence. The method, which takes roughly three minutes, provides actionable molecular information during surgery, potentially guiding treatment decisions and improving patient outcomes.

SourcePurdue University·JournalProceedings of the National Academy of Sciences·DateOct 1, 2026

Loss of Y chromosome in men could be early warning sign of cancer

Researchers found that the loss of the Y chromosome in healthy-seeming tissue can serve as an early indicator of cancer development. The study analyzed 1,000 tissue samples from 405 men and discovered that Y chromosome loss increased in normal tissue adjacent to tumors, particularly in organs like the colon, rectum, and esophagus.

SourceUniversity of Arizona·JournalJCI Insight·TypeRandomized controlled/clinical trial·DateSep 18, 2026

New study identifies a vulnerability in small cell lung cancer – potential therapeutic approach via targeted inhibition

A study from the University of Cologne identified a critical dependency in small cell lung cancer that can be exploited therapeutically. Targeted inhibition of the NMD pathway offers a promising approach to treat SCLC by accumulating mutated proteins and presenting abnormal peptides on the cell surface, making it detectable to the immu...

SourceUniversity of Cologne·JournalMolecular Cancer·TypeExperimental study·DateSep 9, 2026

Bio-Based Fe-MOF nanoreactor builds a redox-cycling strategy for breast cancer therapy

Researchers developed a bio-based Fe-MOF nanoreactor that combines natural-ligand chemistry with multimetallic redox catalysis, biomimetic targeting and MRI visibility. The nanoplatform produced a strong ROS response, increased apoptosis, and tumor inhibition in breast cancer cells and mice.

SourceJournal of Bioresources and Bioproducts·JournalJournal of Bioresources and Bioproducts·TypeExperimental study·DateSep 3, 2026

Aggressive breast cancer sets a trap for itself – and that is just where researchers intend to strike

A University of Helsinki research group has discovered a weakness in aggressive breast cancer cells that can be exploited, targeting the MYC protein's metabolic grip. By inhibiting energy production and glutamine uptake, researchers were able to slow breast cancer growth in mice, paving the way for new and personalised treatments.

SourceUniversity of Helsinki·JournalCell Reports·TypeExperimental study·DateAug 28, 2026

Compendium of patient-derived models offers new opportunities for cancer research, precision oncology

A comprehensive compendium of patient-derived models paired with their original human tumors has been developed, providing powerful tools for understanding tumor biology and predicting treatment response. The resource includes rich molecular profiles that help researchers identify and understand the biological mechanisms driving indivi...

SourceVan Andel Research Institute·JournalNature·DateAug 5, 2026

Combination of targeted therapies could help overcome treatment resistance in advanced prostate cancer

Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of Clinical Investigation·DateAug 3, 2026

Calgary man says clinical trial gave him hope when he had none

Researchers at the University of Calgary have developed a novel CAR T-cell therapy called GCAR1, showing strong preclinical and early clinical promise in treating sarcoma and other cancers. The therapy has been tested on two Canadian patients, with one patient experiencing significant prolongation of life expectancy by 18 months.

SourceUniversity of Calgary·TypeRandomized controlled/clinical trial·DateJul 2, 2026

UCLA researchers awarded $1.7 million Department of Defense grant to advance next-generation CAR T-cell therapies for prostate cancer

Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.

Inducing cell death in pancreatic cancer cells

A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.

SourceUniversity of Cologne·JournalNature Communications·TypeExperimental study·DateJun 16, 2026

UC3M researchers discover how tissue acidosis alters the "transport system" inside cells

A new study by UC3M researchers reveals how extracellular acidosis destabilizes microtubules, the 'avenues' that organize internal cellular traffic, leading to disruptions in cellular function. This finding holds significant implications for understanding pathologies like cancer, diabetes, and certain infectious processes.

SourceUniversidad Carlos III de Madrid·JournalJACS·TypeImaging analysis·DateMay 26, 2026